000163608 001__ 163608
000163608 005__ 20240320115520.0
000163608 0247_ $$2doi$$a10.1007/s11060-021-03913-5
000163608 0247_ $$2pmid$$apmid:35190934
000163608 0247_ $$2pmc$$apmc:PMC8938370
000163608 0247_ $$2ISSN$$a0167-594X
000163608 0247_ $$2ISSN$$a1573-7373
000163608 0247_ $$2altmetric$$aaltmetric:123513577
000163608 037__ $$aDZNE-2022-00354
000163608 041__ $$aEnglish
000163608 082__ $$a610
000163608 1001_ $$aObrecht, Denise$$b0
000163608 245__ $$aClinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.
000163608 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2022
000163608 3367_ $$2DRIVER$$aarticle
000163608 3367_ $$2DataCite$$aOutput Types/Journal article
000163608 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655198547_924
000163608 3367_ $$2BibTeX$$aARTICLE
000163608 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163608 3367_ $$00$$2EndNote$$aJournal Article
000163608 500__ $$a(CC BY)
000163608 520__ $$aTo evaluate the clinical impact of isolated spread of medulloblastoma cells into cerebrospinal fluid without additional macroscopic metastases (M1-only).The HIT-MED database was searched for pediatric patients with M1-only medulloblastoma diagnosed from 2000 to 2019. Corresponding clinical and molecular data was evaluated. Treatment was stratified by age and changed over time for older patients.70 patients with centrally reviewed M1-only disease were identified. Clinical data was available for all and molecular data for 45/70 cases. 91% were non-WNT/non-SHH medulloblastoma (Grp3/4). 5-year PFS for 52 patients ≥ 4 years was 59.4 (± 7.1) %, receiving either upfront craniospinal irradiation (CSI) or SKK-sandwich chemotherapy (CT). Outcomes did not differ between these strategies (5-year PFS: CSI 61.7 ± 9.9%, SKK-CT 56.7 ± 6.1%). For patients < 4 years (n = 18), 5-year PFS was 50.0 (± 13.2) %. M1-persistence occurred exclusively using postoperative CT and was a strong negative predictive factor (pPFS/OS < 0.01). Patients with additional clinical or molecular high-risk (HR) characteristics had worse outcomes (5-year PFS 42.7 ± 10.6% vs. 64.0 ± 7.0%, p = 0.03). In n = 22 patients ≥ 4 years with full molecular information and without additional HR characteristics, risk classification by molecular subtyping had an effect on 5-year PFS (HR 16.7 ± 15.2%, SR 77.8 ± 13.9%; p = 0.01).Our results confirm that M1-only is a high-risk condition, and further underline the importance of CSF staging. Specific risk stratification of affected patients needs attention in future discussions for trials and treatment recommendations. Future patients without contraindications may benefit from upfront CSI by sparing risks related to higher cumulative CT applied in sandwich regimen.
000163608 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000163608 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163608 650_7 $$2Other$$aCerebrospinal fluid
000163608 650_7 $$2Other$$aChildren
000163608 650_7 $$2Other$$aMedulloblastoma
000163608 650_7 $$2Other$$aMetastases
000163608 650_7 $$2Other$$aRadiotherapy
000163608 650_2 $$2MeSH$$aCerebellar Neoplasms: drug therapy
000163608 650_2 $$2MeSH$$aCerebellar Neoplasms: therapy
000163608 650_2 $$2MeSH$$aChild
000163608 650_2 $$2MeSH$$aCraniospinal Irradiation
000163608 650_2 $$2MeSH$$aHumans
000163608 650_2 $$2MeSH$$aMedulloblastoma: drug therapy
000163608 650_2 $$2MeSH$$aMedulloblastoma: therapy
000163608 650_2 $$2MeSH$$aRisk Factors
000163608 7001_ $$aMynarek, Martin$$b1
000163608 7001_ $$aHagel, Christian$$b2
000163608 7001_ $$aKwiecien, Robert$$b3
000163608 7001_ $$aSpohn, Michael$$b4
000163608 7001_ $$aBockmayr, Michael$$b5
000163608 7001_ $$aBison, Brigitte$$b6
000163608 7001_ $$aPfister, Stefan M$$b7
000163608 7001_ $$aJones, David T W$$b8
000163608 7001_ $$aSturm, Dominik$$b9
000163608 7001_ $$avon Deimling, Andreas$$b10
000163608 7001_ $$aSahm, Felix$$b11
000163608 7001_ $$avon Hoff, Katja$$b12
000163608 7001_ $$aJuhnke, B-Ole$$b13
000163608 7001_ $$aBenesch, Martin$$b14
000163608 7001_ $$aGerber, Nicolas U$$b15
000163608 7001_ $$aFriedrich, Carsten$$b16
000163608 7001_ $$avon Bueren, André O$$b17
000163608 7001_ $$aKortmann, Rolf-Dieter$$b18
000163608 7001_ $$aSchwarz, Rudolf$$b19
000163608 7001_ $$0P:(DE-2719)2812617$$aPietsch, Torsten$$b20$$udzne
000163608 7001_ $$aFleischhack, Gudrun$$b21
000163608 7001_ $$0P:(DE-2719)9000979$$aSchüller, Ulrich$$b22$$udzne
000163608 7001_ $$00000-0002-5446-9571$$aRutkowski, Stefan$$b23
000163608 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-021-03913-5$$gVol. 157, no. 1, p. 37 - 48$$n1$$p37 - 48$$tJournal of neuro-oncology$$v157$$x0167-594X$$y2022
000163608 8564_ $$uhttps://pub.dzne.de/record/163608/files/DZNE-2022-00354.pdf$$yOpenAccess
000163608 8564_ $$uhttps://pub.dzne.de/record/163608/files/DZNE-2022-00354.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163608 909CO $$ooai:pub.dzne.de:163608$$pdnbdelivery$$pdriver$$popenaire$$pVDB$$popen_access
000163608 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812617$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000163608 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000979$$aExternal Institute$$b22$$kExtern
000163608 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000163608 9141_ $$y2022
000163608 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000163608 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000163608 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000163608 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2021$$d2022-11-08
000163608 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000163608 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000163608 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163608 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000163608 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-08
000163608 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000163608 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000163608 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000163608 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000163608 9201_ $$0I:(DE-2719)1011009$$kBrainbank Unit Bonn$$lBrainbank Unit Bonn$$x0
000163608 980__ $$ajournal
000163608 980__ $$aVDB
000163608 980__ $$aUNRESTRICTED
000163608 980__ $$aI:(DE-2719)1011009
000163608 9801_ $$aFullTexts